The TRAVERSE study represents a landmark clinical trial investigating cardiovascular safety of testosterone replacement therapy in middle-aged and older men, published in June 2023 in the New England Journal of Medicine.
This research addresses longstanding concerns about potential cardiovascular risks associated with testosterone treatment, providing crucial evidence for clinical decision-making based on rigorous scientific methodology rather than observational data or theoretical concerns.
The study focused on men with clinically diagnosed low testosterone levels and elevated cardiovascular risk factors, offering valuable insights into therapy safety profiles for the population most likely to receive testosterone treatment in real-world practice.
Examining Study Design and Participant Characteristics
This multicenter, randomized, double-blind, placebo-controlled trial enrolled 5,246 men aged 45 to 80 years from 316 sites across the United States, all with documented low testosterone levels (<300 ng/dL) and existing cardiovascular disease or multiple risk factors including hypertension, diabetes, or previous events.
Participants received either testosterone gel (1% topical gel) or placebo gel with follow-up continuing for a median of 33 months, ensuring sufficient time to detect potential cardiovascular events that might develop gradually rather than immediately.
The rigorous design included careful monitoring of cardiovascular events, prostate health indicators, and other safety parameters through regular clinic visits, laboratory testing, and event adjudication by independent committees unaware of treatment assignment, ensuring comprehensive data collection and minimizing bias in outcome assessment.
Analyzing Primary Cardiovascular Safety Outcomes
The investigation revealed no significant increase in major adverse cardiovascular events (MACE) among testosterone users compared to placebo recipients, with hazard ratios showing non-inferiority for the primary endpoint combining cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
Specifically, researchers observed similar rates of heart attacks (1.3% vs 1.2%), strokes (0.7% vs 0.7%), and cardiovascular-related deaths (0.4% vs 0.4%) between testosterone and placebo groups respectively, with confidence intervals excluding clinically important increases in risk.
This finding challenges previous concerns about testosterone therapy potentially increasing cardiovascular risks in vulnerable populations based on earlier observational studies and small trials that suggested possible harm, providing reassurance regarding short-to-medium term cardiovascular safety when used as prescribed in appropriate patients.
Identifying Specific Risk Increases and Safety Considerations
Despite overall cardiovascular safety, the study identified several specific adverse events occurring more frequently in the testosterone group including atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%), though absolute risk increases remained relatively small with number needed to harm of approximately 91-200 for these events.
These findings highlight the importance of individual risk assessment and careful patient selection when considering testosterone therapy, particularly for those with pre-existing cardiac arrhythmias, renal impairment, or hypercoagulable states that might increase vulnerability to these specific complications.
The results suggest that while testosterone doesn’t increase broad cardiovascular risk, clinicians should remain vigilant for these specific potential adverse effects and discuss them with patients during shared decision-making about treatment initiation and monitoring.
Evaluating Prostate Cancer Risk Assessment Results
The TRAVERSE trial provided reassuring data regarding prostate cancer risk, showing no significant difference in prostate cancer incidence between testosterone and placebo groups (0.3% vs 0.2%) during the study period, with hazard ratios indicating no increased risk with active treatment.
This outcome addresses another major concern surrounding testosterone therapy particularly relevant for older male populations who have higher baseline prostate cancer risk, suggesting that testosterone replacement doesn’t significantly promote prostate cancer development or detection over several years of treatment.
Additionally, the study found no significant differences in prostate-specific antigen (PSA) levels between groups, though both showed expected age-related increases, supporting the safety of testosterone regarding prostate health within the study duration and population characteristics.
Considering Clinical Implications and Future Directions
These findings significantly impact clinical practice by providing evidence-based safety data for testosterone therapy in appropriate candidates with symptomatic hypogonadism and cardiovascular risk factors, supporting treatment when indicated rather than avoidance due to theoretical concerns.
Future research will explore additional outcomes including effects on sexual function, bone health, anemia, and quality of life from TRAVERSE data, helping clinicians and patients make more informed treatment decisions balancing potential benefits against individualized risks based on comprehensive assessment.
The results may influence clinical guidelines regarding testosterone use in older men with cardiovascular disease, potentially reducing unnecessary restrictions while maintaining appropriate caution regarding patient selection, monitoring, and management of specific risks identified in this large trial.
Ongoing analysis will provide further insights into longer-term effects beyond the study period and in specific subgroups that might benefit more or require additional precautions during testosterone therapy.
Related topics
